Cabio Biotech Financials
| 688089 Stock | 18.09 0.25 1.40% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 96.8 M | 105.8 M |
|
|
Cabio | Select Account or Indicator |
Understanding current and past Cabio Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cabio Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Cabio Biotech's assets may result in an increase in income on the income statement.
Please note, the presentation of Cabio Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cabio Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cabio Biotech's management manipulating its earnings.
Cabio Biotech Stock Summary
Cabio Biotech competes with Ming Yang, Loctek Ergonomic, Yes Optoelectronics, Hunan Nanling, and Guangdong Tianhe. Cabio Biotech is entity of China. It is traded as Stock on SHG exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| ISIN | CNE100005X31 |
| Business Address | No 999 high-tech |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.cabio.cn |
| Phone | 86 27 6784 5351 |
You should never invest in Cabio Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cabio Stock, because this is throwing your money away. Analyzing the key information contained in Cabio Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Cabio Biotech Key Financial Ratios
Cabio Biotech's financial ratios allow both analysts and investors to convert raw data from Cabio Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of Cabio Biotech over time and compare it to other companies across industries.| Revenue | 443.8 M | ||||
| Gross Profit | 179.62 M | ||||
| EBITDA | 160.2 M | ||||
| Net Income | 91.37 M | ||||
| Total Asset | 1.61 B |
Cabio Biotech Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 1.4B | 1.4B | 1.6B | 1.6B | 1.9B | 1.2B | |
| Retained Earnings | 327.9M | 416.9M | 375.4M | 421.3M | 484.5M | 291.8M | |
| Accounts Payable | 24.5M | 31.4M | 107.3M | 70.9M | 81.5M | 85.6M | |
| Cash | 847.3M | 664.5M | 494.3M | 239.7M | 275.6M | 458.3M | |
| Net Receivables | 128.5M | 151.1M | 189.0M | 214.8M | 247.0M | 149.9M | |
| Inventory | 65.5M | 74.9M | 81.5M | 112.6M | 129.5M | 87.9M | |
| Other Current Assets | 20.9M | 24.7M | 41.8M | 51.3M | 59.0M | 61.9M | |
| Total Liab | 59.3M | 66.7M | 185.8M | 117.6M | 135.2M | 89.2M | |
| Total Current Assets | 1.1B | 994.9M | 907.4M | 708.8M | 815.1M | 790.9M | |
| Intangible Assets | 14.5M | 13.2M | 36.3M | 41.1M | 47.2M | 26.8M | |
| Other Current Liab | 10.3M | 9.6M | 22.6M | 270.6K | 311.2K | 295.6K | |
| Net Invested Capital | 1.3B | 1.4B | 1.5B | 1.5B | 1.7B | 1.2B | |
| Net Working Capital | 1.1B | 934.9M | 726.9M | 596.4M | 685.8M | 779.8M |
Cabio Biotech Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Tax Provision | 22.8M | 20.8M | 16.6M | 13.6M | 15.7M | 17.8M | |
| Net Interest Income | 3.8M | 6.5M | 4.0M | 1.3M | 1.5M | 1.7M | |
| Interest Expense | 3.6M | 351.4K | 366.1K | 595.5K | 684.8K | 856.9K | |
| Total Revenue | 323.5M | 351.1M | 433.4M | 443.8M | 510.4M | 353.1M | |
| Gross Profit | 178.0M | 175.8M | 182.7M | 188.2M | 216.4M | 169.2M | |
| Operating Income | 114.9M | 104.0M | 90.1M | 92.0M | 105.8M | 96.8M | |
| Ebit | 93.9M | 109.8M | 101.7M | 67.7M | 60.9M | 80.5M | |
| Research Development | 20.4M | 30.9M | 32.3M | 38.6M | 44.4M | 25.5M | |
| Cost Of Revenue | 145.5M | 175.3M | 250.8M | 255.6M | 294.0M | 183.9M | |
| Income Before Tax | 157.7M | 152.1M | 78.1M | 100.0M | 115.0M | 120.1M | |
| Net Income | 130.6M | 128.6M | 64.4M | 91.4M | 105.1M | 102.1M | |
| Interest Income | 3.9M | 7.0M | 5.4M | 2.1M | 2.4M | 3.2M | |
| Ebitda | 168.7M | 183.7M | 176.4M | 105.5M | 121.3M | 162.0M | |
| Minority Interest | (4.4M) | (2.7M) | 2.8M | 5.0M | 5.8M | 6.0M |
Cabio Biotech Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Cabio Biotech Wuhan. It measures of how well Cabio is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Cabio Biotech brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Cabio had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Cabio Biotech has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 2.6M | (4.9M) | (9.2M) | (39.6M) | (35.6M) | (33.8M) | |
| Change In Cash | 519.1K | (188.3M) | (165.9M) | (251.0M) | (225.9M) | (214.6M) | |
| Depreciation | 26.0M | 24.0M | 26.6M | 48.3M | 55.6M | 32.4M | |
| Dividends Paid | 60M | 39.9M | 39.8M | 36.6M | 42.1M | 35.7M | |
| Capital Expenditures | 33.1M | 173.4M | 249.5M | 297.7M | 342.3M | 359.4M | |
| Net Income | 130.6M | 128.6M | 64.4M | 91.4M | 105.1M | 102.1M | |
| End Period Cash Flow | 844.8M | 656.6M | 490.6M | 239.7M | 275.6M | 456.4M | |
| Free Cash Flow | 112.8M | (70.1M) | (73.1M) | (228.8M) | (205.9M) | (195.6M) | |
| Other Non Cash Items | (936.9K) | (1.4M) | (6.1M) | 860.9K | 774.8K | 813.6K |
Cabio Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cabio Biotech's current stock value. Our valuation model uses many indicators to compare Cabio Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cabio Biotech competition to find correlations between indicators driving Cabio Biotech's intrinsic value. More Info.Cabio Biotech Wuhan is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.52 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Cabio Biotech Wuhan is roughly 1.91 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cabio Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cabio Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Cabio Biotech Wuhan Systematic Risk
Cabio Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cabio Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Cabio Biotech Wuhan correlated with the market. If Beta is less than 0 Cabio Biotech generally moves in the opposite direction as compared to the market. If Cabio Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cabio Biotech Wuhan is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cabio Biotech is generally in the same direction as the market. If Beta > 1 Cabio Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Cabio Biotech Wuhan Total Assets Over Time
Cabio Biotech Thematic Clasifications
Cabio Biotech Wuhan is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
| IT | View |
Cabio Biotech January 6, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cabio Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cabio Biotech Wuhan. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cabio Biotech Wuhan based on widely used predictive technical indicators. In general, we focus on analyzing Cabio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cabio Biotech's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.49 | |||
| Information Ratio | 0.0483 | |||
| Maximum Drawdown | 32.7 | |||
| Value At Risk | (7.58) | |||
| Potential Upside | 8.0 |
Complementary Tools for Cabio Stock analysis
When running Cabio Biotech's price analysis, check to measure Cabio Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cabio Biotech is operating at the current time. Most of Cabio Biotech's value examination focuses on studying past and present price action to predict the probability of Cabio Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cabio Biotech's price. Additionally, you may evaluate how the addition of Cabio Biotech to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |